ATRA — Atara Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1604464 ·
Last close
$8.38
Market Cap
$75.51M
52W High
$12.45
52W Low
$4.63
ADV30
76,823
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 516,000 | 392,000 | -3,369,000 | -4,145,000 | 19,997,000 | 8,360,000 | 57,309,000 |
| Dec 2025 | 1,595,000 | 1,491,000 | -2,563,000 | -3,406,000 | 20,235,000 | 8,482,000 | 58,737,000 |
| Sep 2025 | 3,453,000 | 3,338,000 | -3,574,000 | -4,303,000 | 30,167,000 | 5,742,000 | 66,801,000 |
| Jun 2025 | 17,575,000 | 17,021,000 | 3,776,000 | 2,387,000 | 36,902,000 | 16,903,000 | 71,943,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,875,000
Investing CF
$949,000
Financing CF
$19,299,000
CapEx
$-90,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$3.08
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,026,010,000
Inventory
$0
Receivables
$0
ST Investments
$0
EBIT TTM
$-5,831,000
Pretax Income TTM
$-9,436,000
Interest Exp TTM
$3,605,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$23,139,000
EBITDA
$-2,163,000
Free Cash Flow
$-16,998,750
Enterprise Value
$77,235,240
Total Cash
$8,360,000
Total Debt
$10,090,000
Shares Out
9,010,172
Trailing EPS
$-1.22
Book Value
$-4.38
ROE
—
ROA
-3.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 120,772,000 | 35,862,000 | 32,688,000 | 20,235,000 | 58,737,000 | — | -50,940,000 |
| Dec 2024 | 128,940,000 | -83,438,000 | -85,403,000 | 109,098,000 | 206,381,000 | — | -68,717,000 |
| Dec 2023 | 8,573,000 | -276,006,000 | -276,126,000 | 165,504,000 | 264,735,000 | — | -192,977,000 |
| Dec 2022 | 63,573,000 | -280,513,000 | -228,302,000 | 376,420,000 | 249,780,000 | — | -270,430,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CSBR | CHAMPIONS ONCOLOGY, INC. | $74.47M | $5.36 | — |
| GNTA | Genenta Science S.p.A. | $71.84M | $1.49 | — |
| CGTX | COGNITION THERAPEUTICS INC | $79.65M | $0.89 | — |
| KLRS | Kalaris Therapeutics, Inc. | $83.51M | $3.51 | — |
| ENZN | Viskase Holdings, Inc. | $67.50M | $4.71 | — |
News headlines (Yahoo Finance, 1h cache)
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
2026-06-17 20:15 · Yahoo
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
2026-05-21 14:37 · Yahoo
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
2026-05-07 15:03 · Yahoo
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
2026-04-03 00:02 · Yahoo
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
2026-04-01 12:01 · Yahoo
Atara Biotherapeutics: Q4 Earnings Snapshot
2026-03-16 20:35 · Yahoo
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
2026-03-03 11:52 · Yahoo
Top Midday Decliners
2026-01-13 19:14 · Yahoo
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
2026-01-12 11:24 · Yahoo
Epstein Barr Virus Research Analysis Report 2025-2035: Market Led by AstrViracta, Atara, AlloVir, and Pierre Fabre as Antiviral and Immune-Modulating Therapy Innovation Accelerates
2025-11-18 15:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.